• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Evaluation of amlodipine dosing for conversion of nifedipine extended-release to amlodipine in the treatment of hypertension.

作者信息

Yamreudeewong W, Halverson V J, Lower D L, Kilpatrick D M, Enlow A M, Montopoli G

机构信息

School of Pharmacy, University of Wyoming, Laramie, USA.

出版信息

Ann Pharmacother. 1999 Jan;33(1):7-10. doi: 10.1345/aph.18177.

DOI:10.1345/aph.18177
PMID:9972377
Abstract

OBJECTIVE

To evaluate the appropriate dosing of amlodipine when converting patients from nifedipine extended-release (nifedipine ER) to amlodipine in the treatment of hypertension.

METHODS

Patients of the Outpatient Clinic of Cheyenne Veterans Affairs Medical Center, Wyoming, receiving nifedipine ER for the management of hypertension (systolic BP or SBP > 140 mm Hg and diastolic BP or DBP > 90 mm Hg), participated in this study. Nifedipine ER was changed to amlodipine on entry into this study. An inclusion criterion was the BP had to be under control (SBP < 140 mm Hg and DBP < 90 mm Hg) before the switch. The BP in each study patient was monitored once weekly (once every 2 wk in some patients) for a total of six clinic visits or until BP was under control. Dosing titration of amlodipine was required in 16 of 27 patients after the switch. To assess the adequacy of the conversion, the statistical significance of the difference of the mean BP values before and at the end of the monitoring period was estimated by using the t-test for paired data.

RESULTS

Twenty-seven male patients completed this study. BP in all study patients was adequately controlled after nifedipine ER was switched to amlodipine. The SBP and DBP values before and after the switch were similar (SBP: 124 +/- 12 vs. 126 +/- 9 mm Hg, CI of the mean difference -6.10 to 1.80; DBP: 76 +/- 8 vs. 76 +/- 7 mm Hg, CI of the mean difference -2.45 to 3.63). Initial amlodipine dose of 5 or 10 mg once daily was used in our study. No serious adverse effects were observed in any of the study patients after the drug switch.

CONCLUSIONS

This study indicates the amlodipine dosage of 5 or 10 mg once daily can be used when nifedipine ER is converted to amlodipine in the treatment of hypertension. Dosage titration of amlodipine may be required to obtain adequate control of BP.

摘要

相似文献

1
Evaluation of amlodipine dosing for conversion of nifedipine extended-release to amlodipine in the treatment of hypertension.
Ann Pharmacother. 1999 Jan;33(1):7-10. doi: 10.1345/aph.18177.
2
Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study.非洛地平缓释片、氨氯地平和硝苯地平控释片对轻至中度动态高血压患者24小时血压控制及谷峰比值的比较效应:一项强制滴定研究。
Can J Cardiol. 1998 May;14(5):682-8.
3
Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release.氨氯地平与硝苯地平缓释片相比的依从性和降压疗效。
Am J Hypertens. 1998 Apr;11(4 Pt 1):478-86. doi: 10.1016/s0895-7061(97)00485-8.
4
Pharmacist-managed hypertension therapy conversion.
Mil Med. 2001 Oct;166(10):866-70.
5
Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers.氨氯地平转换为其他钙通道阻滞剂的回顾性评估。
Pharmacotherapy. 2000 Sep;20(9):1072-8. doi: 10.1592/phco.20.13.1072.35022.
6
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.氨氯地平/雷米普利联合用药与氨氯地平单药治疗高血压的18周前瞻性随机双盲多中心研究:氨氯地平/雷米普利联合治疗评估(ATAR)研究
Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.
7
Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension. Hypertension Study Group.硝苯地平控释片与氨氯地平治疗轻至中度原发性高血压患者的疗效和安全性比较。高血压研究组。
Clin Ther. 1995 Jul-Aug;17(4):686-700. doi: 10.1016/0149-2918(95)80045-x.
8
Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension.尼索地平缓释片与氨氯地平在非裔美国高血压患者中的疗效和安全性比较(CESNA-III研究)
Am J Hypertens. 2003 Sep;16(9 Pt 1):739-45. doi: 10.1016/s0895-7061(03)00946-4.
9
A randomised crossover comparison of reserpine and sustained-release nifedipine in hypertension.利血平和缓释硝苯地平治疗高血压的随机交叉对照研究
Cent Afr J Med. 1997 Dec;43(12):344-9.
10
Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.中重度高血压患者从高剂量钙通道阻滞剂治疗转换为氨氯地平/贝那普利固定剂量联合治疗的疗效与安全性
J Hum Hypertens. 2001 Aug;15(8):559-65. doi: 10.1038/sj.jhh.1001230.